WaveMan
WaveMan · Company
QNRX · Quoin Pharmaceuticals Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

QNRX Quoin Pharmaceuticals (QNRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001671502
Quote by TradingView
Cluster · 4 insidersC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter

What the filings say about QNRX

Insiders, 180 days
+$280.0K net bought
4 buyers

Quoin Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Quoin Pharmaceuticals Ltd. insiders bought a net $280.0K of stock across 23 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Culverwell Anthony James
Director
BUY
2026-09-01 SECtraded 2026-08-31
6,146
$30.0K
-40.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 23, 2024.
  • The trade is 15.2% of the 40,364 shares held after it.
  • 3 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Culverwell Anthony James bought about $30.0K of QNRX on Aug 31, 2026; 3 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Lawlor Sally Bridget
Chief Financial Officer
BUY
2026-09-01 SECtraded 2026-08-31
10,244
$50.0K
-40.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 95.9% of the 10,684 shares held after it.
  • 3 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Lawlor Sally Bridget bought about $50.0K of QNRX on Aug 31, 2026; 3 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Carter Denise P.
Chief Operating Officer
BUY
2026-09-01 SECtraded 2026-08-31
20,490
$100.0K
-40.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Dec 23, 2024.
  • -6.2% median (-15.7% mean) 90-day return after 3 previous buys.
  • The trade is 54.3% of the 37,709 shares held after it.
  • 3 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Carter Denise P. bought about $100.0K of QNRX on Aug 31, 2026; 3 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Myers Michael
Chief Executive Officer
BUY
2026-09-01 SECtraded 2026-08-31
20,490
$100.0K
-40.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Dec 23, 2024.
  • -6.2% median (-15.7% mean) 90-day return after 3 previous buys.
  • The trade is 54.3% of the 37,713 shares held after it.
  • 3 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Myers Michael bought about $100.0K of QNRX on Aug 31, 2026; 3 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
LANGER DENNIS
Director
BUY
2025-10-15 SECtraded 2025-10-14
15,152
$128.6K
-70.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 7, 2024.
  • The trade is 100.0% of the 15,153 shares held after it.
  • No other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LANGER DENNIS bought about $128.6K of QNRX on Oct 14, 2025; 10 funds added in the latest 13F quarter.
23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 18 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$280.0K over 180 days
+$280.0K over 90 days
more than 82% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 82% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 92% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 insiders independently bought a net $280.0K while the stock fell 27% over six months, with no planned sales queued.
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch QNRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-70.1%12M
-76%-28%+19%+66%2025-102025-122026-022026-042026-062026-082026-10 2026-08-31 · Carter Denise P. bought $100.0K2026-08-31 · Myers Michael bought $100.0K2026-08-31 · Lawlor Sally Bridget bought $50.0K2026-08-31 · Culverwell Anthony James bought $30.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns QNRX: institutional holders (13F)

13F holdings, latest reported quarter
Stonepine Capital Management, LLC
965,032 sh
$3.0M
Dauntless Investment Group, LLC
214,987 sh
$1.0M
Ikarian Capital, LLC
211,538 sh
$1.0M
MILLENNIUM MANAGEMENT LLC
112,323 sh
$543.6K
SummitTX Capital, L.P.
100,300 sh
$485.5K

Congress trades in QNRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

QNRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Multi-phase
4 active
What changed recently
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
2026-09-01 · Completion moved 2026-07-30 → 2026-12-30
PHASE2,PHASE3
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndro
2026-09-01 · Completion moved 2025-12-30 → 2026-12-30
PHASE2,PHASE3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $280.0K bought by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

QNRX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-575.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-178.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Net income-$15.8M-$9.0M-$8.7M-$9.4M
Operating cash flow-$13.5M-$7.9M-$7.9M-$8.5M
Cash$3.8M$3.6M$2.4M$2.9M
SEC XBRL, fiscal years, as known on 2026-10-28

QNRX Stock Sonar score 4/7 axes

Find similar shapesCompare

QNRX ranks highest on insider conviction (88th percentile) and risk and compliance (49th), and lowest on profitability (9th), among Pharma & Biotech peers.

Profitability
9
Inputs
  • Return on equity-575.6% · 6 pct, sector of 545
  • Return on assets-178.7% · 12 pct, sector of 691
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Insider conviction
88
Inputs
  • Net Form 4 buying (codes P and S), 180d$280K · 82 pct, sector of 429
  • Insider buyers, 180d4 · 94 pct, sector of 438
Institutional and government
17
Inputs
  • Funds adding, latest quarter10 · 18 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$80K · 16 pct, sector of 133
Risk and compliance
49
Inputs
  • Short interest, % of float+1.1% · 80 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+19.0% · 19 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

QNRX filings, in plain words

Are Quoin Pharmaceuticals insiders buying or selling QNRX?

In the 180 days to 2026-10-28, Quoin Pharmaceuticals insiders were net buyers, a net $280.0K across purchases and sales reported on Form 4, by 4 buyers.

Read the full summary

In the 180 days to 2026-10-28, Quoin Pharmaceuticals insiders were net buyers of QNRX, a net $280.0K across purchases and sales reported on Form 4 by 4 buyers. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies